Non-Alcoholic Fatty Liver Disease Trial, Recruiting (NCT05697991)

Non-Alcoholic Fatty Liver Disease Trial, Recruiting NCT05697991 Sponsor: King Saud University Condition: Non-Alcoholic Fatty Liver Disease

Printed from Voxsanity (voxsanity.com.au) — NCT05697991 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Non Alcoholic Fatty Liver Disease

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

People who have given their written agreement to participate before any screening takes place
Men and women between 18 and 60 years of age
People who have been diagnosed with type 2 diabetes

Who may not be able to join:

People whose liver has stopped working properly, shown by symptoms such as fluid build-up in the abdomen, yellowing of the skin or eyes, or confusion caused by liver failure
People who already have liver cancer
People who have another type of cancer, whether in the liver or elsewhere in the body
People who have previously had a heart attack, a serious heart event caused by blocked arteries, a stroke, or a temporary stroke-like episode
People who have previously had heart bypass surgery, a procedure to open blocked heart arteries (angioplasty), or a stent placed in a heart artery
People with any other health or personal circumstances that, in the opinion of the trial investigators, might prevent them from completing the trial safely and as planned (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 28 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Assim Alfadda, MD, King Saud University

Phone: 0557021171

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT05697991

Sponsor: King Saud University

Phase: Not Applicable

Status: Recruiting

Condition: Non-Alcoholic Fatty Liver Disease

Trial contact: 0557021171

More information: https://clinicaltrials.gov/study/NCT05697991

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

People who have given their written agreement to participate before any screening takes place
Men and women between 18 and 60 years of age
People who have been diagnosed with type 2 diabetes

Who may not be able to join:

People whose liver has stopped working properly, shown by symptoms such as fluid build-up in the abdomen, yellowing of the skin or eyes, or confusion caused by liver failure
People who already have liver cancer
People who have another type of cancer, whether in the liver or elsewhere in the body
People who have previously had a heart attack, a serious heart event caused by blocked arteries, a stroke, or a temporary stroke-like episode
People who have previously had heart bypass surgery, a procedure to open blocked heart arteries (angioplasty), or a stent placed in a heart artery
People with any other health or personal circumstances that, in the opinion of the trial investigators, might prevent them from completing the trial safely and as planned (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 28 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

King Saud University

Registry

ClinicalTrials.gov

Start date

23 March 2015

Est. completion

23 April 2030

Where this trial is recruiting

🇸🇦 Saudi Arabia

Primary endpoints

Prevalence of hepatic steatosis in T2DM

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov